Akèy › Limfom selil mantèl › Kalifòni
Etid klinik pou Limfom selil mantèl nan Kalifòni
29 etid pou Limfom selil mantèl ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
- Baldwin Park15 etid
- Mountain View7 etid
- Los Angeles7 etid
- San Diego5 etid
- San Francisco4 etid
- Irvine3 etid
Tèks ofisyèl etid la (Anglè)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Tower Cancer Research Foundation, Beverly Hills
- Cedars-Sinai Medical Center, Los Angeles
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05976763Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- University of California, Davis, Davis
- University of California, Los Angeles, Los Angeles
- University of California, San Diego, San Diego
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06252675A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, La Jolla
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Ucsf Fresno, Fresno
- Kaiser Permanente Southern California, Irvine
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- Stanford Cancer Center, Stanford
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06553872A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- City of Hope Comprehensive Cancer Center, Duarte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07003295A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07691606AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Stanford University, Palo Alto
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Cedars-Sinai Medical Center, Los Angeles
Ap rekriteFaz 1
Laj 18 a 85 · Tout sèks · Mizajou Aug 10, 2026 · NCT05887167Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06675123A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Los Angele, Los Angeles
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- City of Hope, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT07121946DALY II USA/ MB-CART2019.1 for DLBCL
- UC San Diego Health, La Jolla
- Stanford University, Stanford
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT04545762Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- City of Hope Medical center, Duarte
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT03523975Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 20, 2026 · NCT06859008The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- ak 1 plis
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04830137Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 13, 2026 · NCT06572618Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 23, 2026 · NCT05432635Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 5, 2026 · NCT06054776AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- UC Irvine Health, Orange
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 10, 2025 · NCT05602363BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- City of Hope Medical Center, Duarte
- Stanford University, Stanford
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 20, 2025 · NCT05370430SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- ak 3 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Stanford Cancer Center, Palo Alto
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 22, 2024 · NCT05255354Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.